Evidence map›Paper›PMID 39814099›Full record

ReviewThe American journal of pathology2025

Beyond Redox Regulation: Novel Roles of TXNIP in the Pathogenesis and Therapeutic Targeting of Kidney Disease.

Chuang Li, Yili Fang, Ying Maggie Chen

Abstract readReview
In one paragraph

Review in The American journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chuang LiDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Yili FangDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Ying Maggie ChenDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri; Department of Cell Biology & Physiology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: ychen32@wustl.edu.

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Therapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI QUAGGIN, SUSAN E. · 2018 to 2022
$5.7M
PODOCYTE ENDOPLASMIC RETICULUM STRESS AND NEPHROTIC SYNDROMER01DK105056 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2017 to 2025
$4.5M
Mutant Laminin Chains and Nephrotic SyndromeK08DK089015 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2010 to 2014
$641k
Ultrabright Plasmonic-Fluor Nanosensor-Enabled Noninvasive Management of Pediatric Nephrotic SyndromeR21DK131557 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE, SINGAMANENI, SRIKANTH · 2022 to 2022
$236k
Develop Autophagy Activators to Treat Autosomal Dominant Tubulointerstitial Kidney DiseaseR56DK138158 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2024 to 2024
$200k
PHARMACOLOGICAL RESCUE OF MUTANT LAMININ IN NEPHROTIC SYNDROMER03DK106451 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2015 to 2016
$153k
BLRD VA I01 BX006401NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NIDDK NIH HHS K08 DK089015NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK079337NIDDK NIH HHS P30 DK114857NIDDK NIH HHS R01 DK105056NIDDK NIH HHS R03 DK106451NIDDK NIH HHS R21 DK131557NIDDK NIH HHS R56 DK138158
6 · The paper itself

Abstract

Cellular stress, such as oxidative and endoplasmic reticulum (ER) stresses, contributes to the development of various kidney diseases. Oxidative stress is prompted by reactive oxygen species accumulation and delicately mitigated by glutathione and thioredoxin (Trx) antioxidant systems. Initially identified as a Trx-binding partner, Trx-interacting protein (TXNIP) is significantly up-regulated and activated by oxidative and ER stresses. The function of TXNIP is closely linked to its subcellular localizations. Under normal physiological conditions, TXNIP primarily localizes to the nucleus. When exposed to reactive oxygen species or ER stress, TXNIP relocates to mitochondria and binds to mitochondrial Trx2, which releases Trx-tethered apoptosis signal-regulating kinase 1 and activates apoptosis signal-regulating kinase 1-mediated apoptosis. Oxidative and ER stresses are also closely associated with autophagy. TXNIP can promote or inhibit autophagy depending on context. Although recent studies have highlighted the indispensable role of TXNIP in the etiology and progression of kidney disease, TXNIP-targeted therapy is still missing. This review focuses on the following: i) oxidative and ER stresses; ii) regulation and function of TXNIP during cellular stress; iii) TXNIP in stress-regulated autophagy; iv) TXNIP in kidney diseases (nephrotic syndrome, diabetic nephropathy and chronic kidney disease, acute kidney injury, and kidney aging); and v) novel treatment agents targeting TXNIP in kidney disease. Current advances in chemical compounds and RNA-based therapy suppressing TXNIP are also reviewed.

Indexed as

Carrier ProteinsKidney DiseasesAnimalsEndoplasmic Reticulum StressHumansOxidation-ReductionOxidative StressReactive Oxygen SpeciesThioredoxinsCarrier ProteinsReactive Oxygen SpeciesThioredoxinsTXNIP protein, human

Identifiers

PMID39814099
PMCPMC11959421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.